885950-46-9

Basic information

• Product Name: 5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester
• Synonyms: 5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester;Methyl 1,6-dihydro-5-iodo-6-oxonicotinate, 1,2-Dihydro-3-iodo-5-(methoxycarbonyl)-2-oxopyridine;methyl 5-iodo-6-oxo-1,6-dihydropyridine-3-carboxylate
• CAS NO: 885950-46-9
• Molecular Formula: C₇H₆INO₃
• Molecular Weight: 279.03191
• EINECS: -0
• Mol File: 885950-46-9.mol
• Article Data: 5

Chemical Properties

• Melting Point: 209～211℃
• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester(885950-46-9)
• EPA Substance Registry System: 5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester(885950-46-9)

Safety Data

• Hazardous Substances Data: 885950-46-9(Hazardous Substances Data)

Usage

General Description

5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester is a chemical compound with the molecular formula C8H8INO3. It is a methyl ester derivative of a pyridine carboxylic acid, and it contains an iodo group as well as a carbonyl group on the six-membered ring. 5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester may have potential applications in the field of medicinal chemistry, due to its structural features and reactivity. It is important to handle and use this chemical with caution, as it may present certain hazards if not properly handled and stored.

Upstream product

• 67-56-1 methanol 
• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 
• 66171-50-4 methyl 6-hydroxynicotinate 

Downstream Products

• 1346446-87-4 (3,4-dihydro-2H-pyrano[2,3-b]pyridin-6-yl)methanol 
• 1360952-35-7 methyl 6-chloro-5-(trifluoromethyl)nicotinate 
• 73781-91-6 6-Chloronicotinic acid methyl ester 
• 56055-54-0 methyl 2,3-dichloro-pyridine-5-carboxylate 
• 1391132-73-2 C₁₆H₁₇NO₄S 
• 1391132-72-1 C₁₆H₁₇NO₄S 
• 1361567-63-6 C₁₃H₈Cl₃NO₂ 
• 365413-29-2 6-chloro-5-iodonicotinic acid methyl ester 
• 1373754-96-1 5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinic acid 
• 1361748-71-1 6-chloro-5-(3,4-dichloro-phenyl)-nicotinic acid 
• 1269826-44-9 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide 
• 1007170-49-1 methyl 5-[3-(benzyloxy)-4-chlorophenyl]-6-oxo-1,6-dihydropyridine-3-carboxylate 
• 122534-94-5 furo[2,3-b]pyridine-5-carboxylic acid 

Relevant articles and documents

Imidazole-containing condensed tricyclic compound and application thereof

The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.

PROCESS FOR THE PREPARATION OF NICOTINAMIDE DERIVATIVES

The present invention relates to a process for the preparation of nicotinamide derivatives of the formula (I) R1 to R7 are as defined in the and to pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful for the treatment and / or prophylaxis of diseases which are associated with the modulation of cannabinoid 1 receptors (CB 1 receptors) as described in the PCT Publ. WO 2006/106054.

Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5- carboxamide, an agonist of the α7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: Synthesis and structure-activity relationship

N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (14, PHA-543,613), a novel agonist of the α7 neuronal nicotinic acetylcholine receptor (α7 nAChR), has been identified as a potential treatment of cognitive deficits in schizophrenia. Compound 14 is a potent and selective a7 nAChR agonist with an excellent in vitro profile. The compound is characterized by rapid brain penetration and high oral bioavailability in rat and demonstrates in vivo efficacy in auditory sensory gating and, in an in vivo model to assess cognitive performance, novel object recognition.